Glenmark Pharmaceuticals Limited has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial, expanding its global injectables portfolio. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa® IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. According to IQVIA® sales data for the 12-month period ending May 2026, the Zyprexa® IntraMuscular Injection market achieved annual sales of approximately $25.4 million, supporting market penetration potential for this therapeutic offering.
The launch Glenmark's strategic focus on growing its injectables portfolio and expanding presence within the institutional channel. Marc Kikuchi, President & Business Head, North America, commented that the release reflects the company's continued commitment to expanding access to quality and affordable treatment options for patients and healthcare providers. Glenmark's Olanzapine for Injection is only approved for the specific indication(s) listed in Glenmark's approved label, which may be different than the approved RLD indications.
Glenmark's global presence includes 11 manufacturing facilities across four continents, supported by six cutting-edge R&D centers. The company operates in 80+ countries with a diversified portfolio across branded, innovative, generics, and consumer health products. Glenmark ranks among the Top 100 biopharmaceutical companies globally by pharmaceutical sales, as recognized by Scrip 100 for 2024. The company is led by Rashmi Khandelwal, Company Secretary & Compliance Officer, based in Mumbai, India.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.